Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study
José Luis Pérez-Gracia 1 , Daniel Castellano 2 , Miguel Ángel Climent 3 , Begoña Mellado 4 , Cristina Suárez 5
The introduction of targeted therapy for the treatment of advanced renal cell carcinoma (RCC) has improved the outcome of these patients in the last decade. However, many patients still relapse.
The aim of this consensus study was to establish common recommendations about the best treatment options in patients with RCC. A two-round Delphi methodology was used.
A total of 25 statements were submitted to a panel of 30 specialists. If consensus was not obtained in the first round a second and last round was performed.
Agreement was achieved for 19 of the proposed 25 statements (76%). When making a decision about the treatment option, considering the efficiency and response rate to previous treatment, drug's toxicity and the patients' clinical features are very relevant.
CITA DEL ARTÍCULO Med Oncol. 2019 Feb 19;36(3):29. doi: 10.1007/s12032-019-1251-7